After decades of limited progress, the development of novel anti-TB medicines was revitalised at the start of the 21st century through new initiatives and investments. This has resulted in innovations in treatment regimens thanks to new compounds becoming available and the re-purposing of existing drugs. However, progress has been relatively slow for a disease that, until the emergence of the COVID-19 pandemic, has remained the top infec- tious killer worldwide. Accelerated action is there- fore necessary to reach the ambitious target of ‘‘ending TB’’ set by the WHO within its new Global Strategy (2016–2030). Read Here.
top of page
Recent Posts
See AllThe Indonesia AIDS Coalition (IAC) and Indonesia for Global Justice (IGJ) have filed a patent opposition for the Tuberculosis (TB) drug Bedaquiline with dispersible tablet formulations (hereinafter, i
340
Calls for strengthening health systems in preparation for the next pandemic have intensified in the wake of COVID-19, with estimates ranging from $15 billion to $50 billion needed annually to scale up
530
The monitoring and evaluation framework of the TB Action Plan for the WHO European Region 2023–2030 includes four new indicators reflecting consistent meaningful engagement of the communities and civi
540
bottom of page